

Feb. 26, 2025_FINAL_V3
(circulating for signatures)

Dear Government Representatives and Health Officials:

Canadian Open Letter of Concern regarding COVID-19 mRNA Vaccines

As qualified Canadian and international researchers and professionals, we are extremely concerned as evidence questioning the quality, efficacy and safety of the COVID-19 mRNA (more precisely, modified mRNA or modRNA) vaccines continues to mount.

Given the accumulating evidence of concern, on behalf of the Canadian public, we call on you, our government representatives and public health officials, for:

- **An immediate halt to the use of and a recall of the COVID-19 mRNA vaccine products.**
- **An independent and transparent public inquiry** into the regulatory processes leading to the approval of these products and their ongoing use.
- **Scientific assessments and analyses of all mRNA products** to determine the health risks to humans from residual plasmid DNA, potential aberrant protein production, and shift to IgG4 antibodies.
- **Access to data and funding for independent research** to assess the potential link between the COVID-19 mRNA vaccines and the recent probable increase in cancer rates and mortality,^{1,2} including any association with the SARS-CoV-2 virus itself.

Our plea for your immediate action is based on many scientifically-supported concerns regarding the COVID-19 mRNA products,³ the latest of which are outlined below:

- **Variable and concerning levels of residual plasmid DNA have been found in the COVID-19 mRNA products** in vials from Canada,⁴ the USA,⁵ France,⁶ Germany,^{7,8} and Australia,⁹ as well as by independent research conducted at a US Food and Drug Administration (FDA) facility.¹⁰ Residual DNA is undesirable as it has potential oncogenic and infectious risks.¹¹ This concern is further compounded by the fact that **lipid nanoparticles (LNPs)**, in which the COVID-19 mRNA products are encased, **increase the delivery of foreign DNA across cell membranes by 10-100 times.**^{12,13} The current regulatory limit of residual DNA does **not** account for this effect.
- **Undisclosed bioactive SV40 promoter-enhancer DNA sequences are used in the production of the Pfizer/BioNTech vaccines.**^{4,5} This has been confirmed by Health Canada,¹⁴ the US FDA,¹⁵ and the European Medicines Agency (EMA),¹⁶ and is highly concerning because these SV40 sequences

are used in gene therapy to transport foreign DNA into the cell nucleus and facilitate DNA integration into the human genome.¹⁷ These sequences should not be present in vaccines; as stated by Health Canada scientists, these sequences "serve no purpose in the manufacturing of Pfizer COVID-19 vaccines" and are "not present in any vaccines currently approved in Canada."¹⁸ Irrespective of the potential health risks associated with these sequences, the lack of disclosure to Health Canada¹⁴ and other regulators by the manufacturer *alone* is a violation of World Health Organization (WHO) Guidelines for mRNA vaccines that require *all* sequences in the DNA starting material to be annotated and justified.¹⁹

- **Numbers of reported vaccine adverse events are batch specific.**^{20,21,22,23} Multiple analyses of public data by independent research groups have revealed unacceptable inconsistencies in manufacturing, storage, administration and/or delivery of the COVID-19 mRNA vaccines.

Further issues with these mRNA products that have already been *identified by Health Canada scientists* include:

- **Aberrant unintended proteins may be produced due to ribosomal frameshifting.**²⁴ Ribosomes carry out the synthesis of proteins from mRNA instructions inside cells. In ribosomal frameshifting the reading of the instructions is shifted resulting in the production of aberrant unintended proteins. Health Canada scientists have considered these aberrant proteins to represent a "high level of impurity" and "cannot absolutely exclude any possible undesirable effects on cell proliferation or toxicity."²⁵
- **A shift of individuals' antibody immune responses from the expected antibody types (*e.g.*, IgG1, IgG3, and IgA) to IgG4 antibodies has been observed following repeated COVID-19 vaccinations.**²⁶ Health Canada scientists have noted that international bodies, including themselves, have identified this shift.²⁷ IgG4 antibodies are associated with immune tolerance (*i.e.*, more SARS-CoV-2 infection) and serious auto-immune conditions.²⁶

Concerns similar to ours have been raised by many other groups both in Canada and around the world who have also asked for a suspension of the COVID-19 mRNA vaccines. For instance:

- Canadian National Citizens' Inquiry, a citizen-led effort to examine Canada's response to COVID-19, which heard 305 expert and lay witnesses in eight cities (2023)²⁸
- Australian Member of Parliament Russell Broadbent who, supported by 52 scientists and health care professionals, wrote a letter to Australia's Prime Minister (2024)²⁹
- NORTH group, a coalition of scientists, physicians, other professionals, and politicians, who issued letters to the governments of 23 European countries and Canada (2024/25)³⁰
- Alberta COVID-19 Pandemic Data Review Task Force, which concluded that "further research to establish the safety and efficacy of COVID-19 vaccines is necessary before widespread use in adults and children" (2025)³¹

Call to Halt-19 Open Letter
Feb. 26, 2025 (circulating for signatures)

- Réinfo Québec, a collective of health professionals, scientists and citizens in Québec, who recently held a press conference on this matter (2025)³²
- Seventeen other professional public health and physician organizations around the world who have made statements (2021-2024)³³

In order to protect the health of Canadian citizens, we appeal for an immediate halt to the COVID-19 mRNA vaccines and a redirection of efforts towards much needed inquiry, assessment, and research. We hope for a fulsome discussion of the evidence and welcome the opportunity to contribute to the path forward.

With utmost concern and respect,

Canadian researchers and professionals [in alphabetical order]

Claudia Chaufan, MD, PhD, Associate Professor of Health Policy and Management,
York University

York Hsiang, MB, ChB, MHSc, FRCSC, Professor Emeritus of Surgery,
University of British Columbia

Niel A. Karrow, PhD Immunotoxicology, Professor, Department of Animal Biosciences, University
of Guelph

Christian Linard, PhD, DEPD in Clinical Biochemistry, Full Professor,
Université du Québec à Trois-Rivières

Bernard Massie, Retired Researcher and former General Manager at the NRC Human Health
Therapeutic Research Center, and Associate Professor of Microbiology and Immunology

Deanna McLeod, Principal of Research Firm Kaleidoscope Strategic

Phil Oldfield, DPhil, Retired Clinical Biochemist

Steven Pelech, PhD, Professor of Medicine, University of British Columbia

Christopher Pinto, MD

Patrick Provost, PhD, Expert in RNA & lipid nanoparticles, Ex-Full Professor, Université Laval

Christopher A. Shaw, PhD, Professor, Department of Ophthalmology & Visual Sciences, University
of British Columbia

David J. Speicher, PhD DTM, Virologist, University of Guelph

Regina Watteel, PhD Statistics, Independent Researcher

International researchers and professionals [in alphabetical order]

Sponsoring Organizations:



Canadian Citizens Care Alliance
Alliance Canadienne de
Soins pour les Citoyens



- ¹ McLeod, D.; Martins, I.; Tinker, A.; Selk, A.; Brezden-Masley, C.; LeVasseur, N.; Altman, A. Changes in female cancer diagnostic billing rates over the COVID-19 period in the Ontario Health Insurance Plan. medRxiv 2024. <https://doi.org/10.1101/2024.12.17.24319153>
- ² Alegria, C; Nunes, Y. Trends in death rates from neoplasms in the US for all ages and detailed analysis for 75-84. ResearchGate Preprint 2024. <http://dx.doi.org/10.13140/RG.2.2.16221.01760>
- ³ A comprehensive summary of concerns about the Pfizer/BioNTech COVID-19 mRNA vaccine, for instance, can be found in: Oldfield, P. R.; Gutsch, L. M.; McCullough, P. A.; Speicher, D. J. Pfizer/BioNTech's COVID-19 mRNA vaccines: Dangerous genetic mechanism of action released before sufficient preclinical testing. Journal of American Physicians and Surgeons 2024, 29(4), 118-126. <https://jpands.org/vol29no4/oldfield.pdf>
- ⁴ Speicher, D. J.; Rose, J.; Gutsch, L. M.; Wiseman, D. M.; McKernan, K. DNA fragments detected in monovalent and bivalent Pfizer/BioNTech and Moderna mRNA COVID-19 vaccines from Ontario, Canada: Exploratory dose response relationship with serious adverse events. OSF PrePrints 2023. <https://doi.org/10.31219/osf.io/mic97>
- ⁵ McKernan, K.; Helbert, Y.; Kane, L.; McLaughlin, S. Sequencing of bivalent Moderna and Pfizer mRNA vaccines reveals nanogram to microgram quantities of expression vector dsDNA per dose. OSF Preprints 2023. <http://doi.org/10.31219/osf.io/b9t7m>
- ⁶ Raoult, D. Confirmation of the presence of vaccine DNA in the Pfizer anti-COVID-19 vaccine. HAL Open Science 2024. <https://hal.science/hal-04778576v1/document>
- ⁷ Kammerer, U.; Steger, K. BioNTech RNA-based COVID-19 injections contain large amounts of residual DNA including an SV40 promoter/enhancer Sequence. Journal of Science, Public Health Policy and the Law 2024, v5.2019-2024. <https://publichealthpolicyjournal.com/biontech-rna-based-covid-19-injections-contain-large-amounts-of-residual-dna-including-an-sv40-promoter-enhancer-sequence/>
- ⁸ König, B.; Kirchner, J. O. Methodological considerations regarding the quantification of DNA impurities in the COVID-19 mRNA Vaccine Comirnaty®. Methods and Protocols 2024, 7 (3), 41. <https://doi.org/10.3390/mps7030041>
- ⁹ Speicher, D. David Speicher Report. University of Guelph 2024. <https://russellbroadbent.com.au/wp-content/uploads/David-Speicher-Report-2.pdf>
- ¹⁰ Wang, T.J.; Kim, A.; Kim, K. A rapid detection method of replication-competent plasmid DNA from COVID-19 mRNA vaccines for quality control. Journal of High School Science 2024, 8(4), 427-439. <https://jhss.scholasticahq.com/article/127890-a-rapid-detection-method-of-replication-competent-plasmid-dna-from-covid-19-mrna-vaccines-for-quality-control>
- ¹¹ Sheng-Fowler, L.; Lewis, A. M. Jr.; Peden, K. Issues associated with residual cell-substrate DNA in viral vaccines. Biologicals 2009, 37(3), 190-195. <https://doi.org/10.1016/j.biologicals.2009.02.015>
- ¹² Di, J.; Du, Z.; Wu, K.; Jin, S.; Wang, X.; Li, T.; Xu, Y. Biodistribution and non-linear gene expression of mRNA LNPs affected by delivery route and particle size. Pharmaceutical Research 2022, 39 (1), 105-114. <https://doi.org/10.1007/s11095-022-03166-5> from NLM.
- ¹³ Phua, K. K.; Leong, K. W.; Nair, S. K. Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format. Journal of Controlled Release 2013, 166 (3), 227-233. <https://doi.org/10.1016/j.jconrel.2012.12.029> from NLM.
- ¹⁴ Horwood, M. Exclusive: Health Canada confirms undisclosed presence of DNA sequence in Pfizer shot. The Epoch Times (Canada) Nov. 1, 2023. <https://www.theepochtimes.com/world/exclusive-health-canada-confirms-undisclosed-presence-of-dna-sequence-in-pfizer-shot-5513277> (from ATIP HC-A-2023-001013 pg 46 available at https://www.researchgate.net/publication/386986657_ReleasePackage_HC-A-2023-001013_-_2024-08-09_OCR_Noie_Chartiers_August_2024)
- ¹⁵ Marks, P. Response to Dec. 6, 2023 Letter from J. Ladapo, State Surgeon General of Florida. CBER, FDA Dec. 14, 2023. <https://www.fda.gov/media/174875/download>

Call to Halt-19 Open Letter
Feb. 26, 2025 (circulating for signatures)

-
- ¹⁶ Steiber, Z. European regulator confirms BioNTech did not highlight DNA sequence in COVID-19 vaccine. Epoch Times Health (United States) Nov. 3, 2023. <https://www.theepochtimes.com/health/european-regulator-confirms-pfizer-did-not-highlight-dna-sequence-in-covid-19-vaccine-5519668?utm>
- ¹⁷ Dean, D. A.; Dean, B. S.; Muller, S.; Smith, L. C. Sequence requirements for plasmid nuclear import. *Experimental Cell Research* 1999, 253 (2), 713-722. <https://doi.org/10.1006/excr.1999.4716> from NLM.
- ¹⁸ from ATIP HC-A-2023-001013 pg 426 available at https://www.researchgate.net/publication/386986657_ReleasePackage_HC-A-2023-001013_-_2024-08-09_OCR_No Chartiers August 2024
- ¹⁹ World Health Organization. Evaluation of the quality, safety and efficacy of messenger RNA vaccines for the prevention of infectious diseases: Regulatory considerations. In Annex 3, TRS No 1039, WHO 2022. <https://www.who.int/publications/m/item/annex-3-mRNA-vaccines-trs-no-1039>
- ²⁰ Schmeling, M.; Manniche, V.; Hansen, P. R. Batch-dependent safety of the BNT162b2 mRNA COVID-19 vaccine. *European Journal of Clinical Investigation* 2023, 53 (8), e13998. <https://doi.org/10.1111/eci.13998>
- ²¹ Manniche, V.; Schmeling, M.; Gilthorpe, J. D.; Hansen, P. R. Reports of batch-dependent suspected adverse events of the BNT162b2 mRNA COVID-19 vaccine: Comparison of results from Denmark and Sweden. *Medicina* 2024, 60 (8), 1343. <https://doi.org/10.3390/medicina60081343>
- ²² Fürst, T.; Šourek, P.; Krátká, Z.; Janošek, J. Batch-dependent safety of COVID-19 vaccines in the Czech Republic and comparison with data from Denmark. *European Journal of Clinical Investigation* 2024, 54 (10), e14271. <https://doi.org/10.1111/eci.14271> from NLM.
- ²³ Jablonowski K.; Hooker, B. Batch-dependent safety of the BNT162b2 mRNA COVID-19 vaccine in the United States. *Journal of Science, Public Health Policy and the Law* 2024, v5.2019-2024, Research Letter. <https://publichealthpolicyjournal.com/batch-dependent-safety-of-the-bnt162b2-mrna-covid-19-vaccine-in-the-united-states/>
- ²⁴ Mulrone, T.E.; Pöyry, T.; Yam-Puc, J.C.; Rust, M.; Harvey, R.F.; Kalmar, L.; Horner, E.; Booth, L.; Ferreira, A. P.; Stoneley, M.; Sawarkar, R.; Mentzer, A. J.; Lilley, K. S.; Smales, C. M.; von der Haar, T.; Turtle, L.; Dunachie, S.; Klenerman, P.; Thaventhiran, J. E. D.; Willis, A. E. N¹-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting. *Nature* 2024, 625, 189–194. <https://www.nature.com/articles/s41586-023-06800-3>
- ²⁵ Chartier, N. Exclusive: Health Canada official deleted scientist's note saying mRNA shots have "high level of impurity": Internal emails. *The Epoch Times (Canada)* Feb. 23, 2024. <https://www.theepochtimes.com/world/exclusive-health-canada-official-deleted-scientists-note-saying-mrna-shots-have-high-level-of-impurity-internal-emails-5593451> (from ATIP HC-A-2023-001249 pgs 15, 17, 22-23, 26-27. Available at: https://www.researchgate.net/publication/387025365_HC-A-2023-001249_frameshifting)
- ²⁶ Uversky, V. N.; Redwan, E. M.; Makis, W.; Rubio-Casillas, A. IgG4 antibodies induced by repeated vaccination may generate immune tolerance to the SARS-CoV-2 spike protein. *Vaccines (Basel)* 2023, 11 (5). <https://doi.org/10.3390/vaccines11050991> from NLM.
- ²⁷ from ATIP HC-A-2023-001013 pgs 168, 170, 172. Available at: https://www.researchgate.net/publication/386986657_ReleasePackage_HC-A-2023-001013_-_2024-08-09_OCR_No Chartiers August 2024
- ²⁸ National Citizens Inquiry. Final report: Inquiry into the appropriateness and efficacy of the COVID-19 response in Canada, 2023. <https://nationalcitizensinquiry.b-cdn.net/wp-content/uploads/2023/12/FINAL-REPORT-Volume-1-2-Inquiry-into-the-Appropriateness-and-Efficacy-of-the-COVID-19-Response-in-Canada-December-21-2023.pdf>. ISBN 978-1-7382185-5-4. See pg 472.
- ²⁹ Broadbent, R. Letter to Prime Minister. Russell Broadbent, MP, Member for Monash, Australia, Sept. 25, 2024. <https://russellbroadbent.com.au/australiansdemandanswers/>
- ³⁰ The North Group. Notice of extreme concern about COVID-19 modified mRNA vaccine safety and quality, 2024-2025. <https://www.northgroup.info/> (24 countries include: Austria, Belgium, Canada, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Greece, Greenland, Hungary, Iceland, Ireland, Latvia, Lithuania, Malta, The Netherlands, Norway, Portugal, Slovenia, Spain, Sweden, United Kingdom)
- ³¹ Alberta COVID-19 Pandemic Data Review Task Force. Alberta's COVID-19 pandemic response, Final Report, Jan. 24, 2025. <https://open.alberta.ca/publications/albertas-covid-19-pandemic-response>. See Chapter 8 Vaccines, Conclusions and Recommendations on pg 205.
- ³² Réinfo Québec. Jan. 28, 2025 press conference & Nov. 1, 2024 formal notice to the Collège des Médecins du Québec (College of Physicians of Quebec). <https://reinfoquebec.ca/cm/q/>
- ³³ Hulscher, N.; Bowden, M. T.; McCullough, P. A. Review: Calls for market removal of COVID-19 vaccines intensify as risks far outweigh theoretical benefits. *Journal of Science, Public Health Policy and the Law* 2025, v6.2019-2025. <https://publichealthpolicyjournal.com/review-of-calls-for-market-removal-of-covid-19-vaccines-intensify-risks-far-outweigh-theoretical-benefits/>